Aptevo Therapeutics Inc. Line of Credit Facility, Annual Principal Payment
Aptevo Therapeutics Inc. (APVO) reported Line of Credit Facility, Annual Principal Payment of $20.00 million for the 0-month period ending 2020-02-28, per its 10-Q filed 2020-11-10.
Discontinued › Notes › Debt › Line of Credit Facility
us-gaap:LineOfCreditFacilityAnnualPrincipalPayment · last filed 2020-11-10
- 2020-02-28: Line of Credit Facility, Annual Principal Payment 0 month $20.00M.
| Period end | Line of Credit Facility, Annual Principal Payment 0 month |
|---|---|
| 2020-02-28 | $20.00M 10-Q · filed 2020-11-10 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Onconetix, Inc. (ONCO) | United States | $0.004B | |
| Sunshine Biopharma Inc. (SBFM) | $0.003B | ||
| HCW Biologics Inc. (HCWB) | United States | $0.004B | -6.15 |
| REVELATION BIOSCIENCES, INC. (REVB) | United States | $0.004B | |
| Alaunos Therapeutics, Inc. (TCRT) | United States | $0.003B | -1.44 |
| Genprex, Inc. (GNPX) | United States | $0.003B | -0.02 |
| Silo Pharma, Inc. (SILO) | United States | $0.003B | -1.57 |
| 60 DEGREES PHARMACEUTICALS, INC. (SXTP) | United States | $0.004B | -0.59 |
| GeoVax Labs, Inc. (GOVX) | United States | $0.003B | -0.45 |
| Petros Pharmaceuticals, Inc. (PTPI) | United States | $0.003B |